Allogene Therapeutics, Inc. (NASDAQ:ALLO) Insider Sells $25,215.66 in Stock

Allogene Therapeutics, Inc. (NASDAQ:ALLO) insider Timothy L. Moore sold 14,746 shares of Allogene Therapeutics stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $1.71, for a total transaction of $25,215.66. Following the completion of the sale, the insider now directly owns 250,713 shares of the company’s stock, valued at approximately $428,719.23. This trade represents a 5.55 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Allogene Therapeutics Stock Up 1.2 %

Shares of Allogene Therapeutics stock traded up $0.02 during trading on Wednesday, reaching $1.64. The company’s stock had a trading volume of 2,197,203 shares, compared to its average volume of 2,824,648. Allogene Therapeutics, Inc. has a 52-week low of $1.61 and a 52-week high of $5.78. The company has a market cap of $343.86 million, a price-to-earnings ratio of -1.05 and a beta of 0.83. The firm’s 50-day moving average is $2.06 and its two-hundred day moving average is $2.45.

Analyst Ratings Changes

Several equities research analysts have weighed in on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $9.00 price target on shares of Allogene Therapeutics in a research note on Friday, November 8th. Piper Sandler cut their price target on shares of Allogene Therapeutics from $11.00 to $9.00 and set an “overweight” rating on the stock in a report on Thursday, November 14th. Finally, William Blair restated an “outperform” rating on shares of Allogene Therapeutics in a report on Thursday, November 14th. One research analyst has rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to data from MarketBeat, Allogene Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $9.73.

Institutional Investors Weigh In On Allogene Therapeutics

Institutional investors have recently added to or reduced their stakes in the company. Barclays PLC boosted its position in Allogene Therapeutics by 101.5% during the 3rd quarter. Barclays PLC now owns 342,973 shares of the company’s stock valued at $959,000 after buying an additional 172,745 shares during the period. Zacks Investment Management bought a new stake in Allogene Therapeutics in the third quarter worth $1,446,000. Geode Capital Management LLC boosted its holdings in Allogene Therapeutics by 14.4% in the third quarter. Geode Capital Management LLC now owns 3,227,104 shares of the company’s stock worth $9,037,000 after acquiring an additional 407,070 shares in the last quarter. Dimensional Fund Advisors LP boosted its holdings in Allogene Therapeutics by 24.8% in the second quarter. Dimensional Fund Advisors LP now owns 2,550,640 shares of the company’s stock worth $5,944,000 after acquiring an additional 507,021 shares in the last quarter. Finally, The Manufacturers Life Insurance Company lifted its holdings in shares of Allogene Therapeutics by 70.3% during the second quarter. The Manufacturers Life Insurance Company now owns 480,381 shares of the company’s stock valued at $1,119,000 after purchasing an additional 198,231 shares in the last quarter. Hedge funds and other institutional investors own 83.63% of the company’s stock.

Allogene Therapeutics Company Profile

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).